Cyr Financial Inc. Sells 355 Shares of Axon Enterprise, Inc $AXON

Cyr Financial Inc. trimmed its position in Axon Enterprise, Inc (NASDAQ:AXON) by 56.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 278 shares of the biotechnology company’s stock after selling 355 shares during the quarter. Cyr Financial Inc.’s holdings in Axon Enterprise were worth $230,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Jennison Associates LLC grew its position in Axon Enterprise by 23,203.7% in the first quarter. Jennison Associates LLC now owns 614,053 shares of the biotechnology company’s stock valued at $322,961,000 after acquiring an additional 611,418 shares during the last quarter. Nuveen LLC acquired a new stake in shares of Axon Enterprise in the 1st quarter valued at approximately $264,796,000. Westfield Capital Management Co. LP boosted its stake in shares of Axon Enterprise by 29.8% in the 1st quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company’s stock valued at $487,977,000 after purchasing an additional 212,931 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Axon Enterprise by 2.2% during the 1st quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company’s stock valued at $4,540,005,000 after purchasing an additional 185,571 shares during the last quarter. Finally, Axiom Investors LLC DE acquired a new position in Axon Enterprise during the 1st quarter worth approximately $93,088,000. 79.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, insider Jeffrey C. Kunins sold 7,891 shares of the stock in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $750.10, for a total value of $5,919,039.10. Following the transaction, the insider owned 144,538 shares in the company, valued at approximately $108,417,953.80. This represents a 5.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, President Joshua Isner sold 15,919 shares of the business’s stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $746.26, for a total value of $11,879,712.94. Following the sale, the president owned 238,379 shares of the company’s stock, valued at approximately $177,892,712.54. This represents a 6.26% decrease in their position. The disclosure for this sale can be found here. Insiders sold 44,932 shares of company stock worth $34,408,816 in the last quarter. Company insiders own 5.70% of the company’s stock.

Axon Enterprise Price Performance

Axon Enterprise stock opened at $708.84 on Monday. The stock has a market capitalization of $55.64 billion, a price-to-earnings ratio of 175.02, a PEG ratio of 27.53 and a beta of 1.40. Axon Enterprise, Inc has a 52-week low of $388.37 and a 52-week high of $885.91. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. The stock’s 50 day moving average price is $758.60 and its two-hundred day moving average price is $703.76.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.58. The company had revenue of $668.54 million for the quarter, compared to the consensus estimate of $641.77 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. Axon Enterprise’s quarterly revenue was up 32.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.20 EPS. Axon Enterprise has set its FY 2025 guidance at EPS. On average, equities analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on AXON. JPMorgan Chase & Co. raised their price objective on Axon Enterprise from $730.00 to $850.00 and gave the company an “overweight” rating in a report on Thursday, July 17th. Wolfe Research started coverage on Axon Enterprise in a research report on Monday, July 7th. They issued an “outperform” rating for the company. Morgan Stanley set a $885.00 price target on Axon Enterprise and gave the stock an “overweight” rating in a report on Friday, July 11th. Craig Hallum raised Axon Enterprise from a “hold” rating to a “buy” rating and set a $900.00 price objective for the company in a research note on Tuesday, August 5th. Finally, Northland Securities set a $800.00 price objective on shares of Axon Enterprise in a report on Tuesday, August 5th. Fourteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $841.64.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.